Publicaciones en colaboración con investigadores/as de Princess Margaret Hospital (19)

2023

  1. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

2021

  1. SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?

    Journal of Experimental Medicine, Vol. 218, Núm. 6

2019

  1. Effects of ABO matching of platelet transfusions in critically III children

    Pediatric Critical Care Medicine, Vol. 20, Núm. 2, pp. E61-E69

  2. International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children with an Underlying Oncologic Diagnosis

    Pediatric Critical Care Medicine, Vol. 20, Núm. 7, pp. e342-e351

2018

  1. Platelet Transfusion Practices in Critically Ill Children

    Critical Care Medicine, Vol. 46, Núm. 8, pp. 1309-1317

2017

  1. Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma

    Allergologia et Immunopathologia, Vol. 45, Núm. 2, pp. 105-114

  2. New or Progressive Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis: A Sepsis Phenotype With Higher Morbidity and Mortality

    Pediatric Critical Care Medicine, Vol. 18, Núm. 1, pp. 8-16

2016

  1. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low‐dose dexamethasone versus high‐dose dexamethasone in refractory or relapsed and refractory multiple myeloma

    Haematologica, Vol. 101, Núm. 7, pp. 872-878

  2. Comparison of Pediatric Severe Sepsis Managed in U.S. and European ICUs

    Pediatric Critical Care Medicine, Vol. 17, Núm. 6, pp. 522-530

  3. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Haematologica, Vol. 100, Núm. 10, pp. 1327-1333

  2. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 10, pp. 1334-1339

2013

  1. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 14, Núm. 11, pp. 1055-1066

2012

  1. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

    European Journal of Cancer, Vol. 48, Núm. 3, pp. 324-332

2011

  1. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial

    The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283

2008

  1. The diagnosis and management of rectal cancer: Expert discussion and recommendations derived from the 9th world congress on gastrointestinal cancer, Barcelona, 2007

    Annals of Oncology

2001

  1. Monosomy for the most telomeric, gene-rich region of the short arm of human chromosome 16 causes minimal phenotypic effects

    European Journal of Human Genetics, Vol. 9, Núm. 3, pp. 217-225